Results 121 to 130 of about 41,743 (197)

The JAK/STAT Pathway in Cancer: From Molecular Mechanisms to Clinical Applications

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Dysregulated JAK/STAT signaling and related genetic mutations are strongly associated with cancer progression, including promoting tumor proliferation, suppressing apoptosis, inducing immune suppression, participating in drug resistance. Based on the function of the JAK/STAT pathway in disease pathogenesis, numerous agents targeting the JAK/STAT ...
Yixing Liao, Qi Wei, Hongjun Song, Hao Zeng, Chang Qi, Yunchang Meng, Yuanyuan Zhang, Yuanyuan Zhang, Weimin Li, Yalun Li, Panwen Tian   +10 more
wiley   +1 more source

VKH-Like Syndrome in a Patient on Tofacitinib. [PDF]

J Vitreoretin Dis
Tran JH, Hosseini H, Tsui E, Au A.
europepmc   +1 more source

European Society for the Study of Coeliac Disease (ESsCD) 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 2: Management, Follow‐Up, and Complex Disease Courses

United European Gastroenterology Journal, Volume 14, Issue 2, March 2026.
ABSTRACT Introduction Since the publication of the first European Society for the Study of Coeliac Disease (ESsCD) guidelines in 2019, substantial advances have been made in understanding the management and complex disease courses of coeliac disease (CeD) in adults.
Abdulbaqi Al‐Toma, Federica Branchi, Fabiana Zingone, Annalisa Schiepatti, Georgia Malamut, Cristina Canova, Isabella Rosato, Honoria Ocagli, Nick Trott, Luca Elli, Alina Popp, Carmen Gianfrani, Renata Auricchio, Andra Neefjes‐Borst, David S. Sanders, Christophe Cellier, Chris J. Mulder, Gerd Bouma, Knut E. A. Lundin, Ludvig M. Sollid, Michael Schumann   +20 more
wiley   +1 more source

Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA). [PDF]

BMJ Open
Krueger K, Behrens F, Brandt-Juergens J, Detert J, Feuchtenberger M, Prothmann U, Behmer O, Hsieh MM, Jobst J, Klaus P, Meng T.   +10 more
europepmc   +1 more source

A Population‐Based Matched Cohort Study of Extra‐Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 6, Page 859-873, March 2026.
This illustration summarises our primary findings highlighting the rising incidence of certain extra‐digestive cancers among persons with IBD over the 25‐year study duration (left), and the relative rates of extra‐digestive cancer incidence and mortality among persons with IBD in recent years (2010–2019) compared to their age‐ and sex‐matched controls (
Sanjay K. Murthy, Faria Ahmed, Michael Pugliese, Monica Taljaard, Parul Tandon, Priscilla Matthews, Gilaad G. Kaplan, Stephanie Coward, Charles N. Bernstein, Eric I. Benchimol, M. Ellen Kuenzig, Laura E. Targownik, Harminder Singh, on behalf of the Canadian Gastro‐Intestinal Epidemiology Consortium (CanGIEC)   +13 more
wiley   +1 more source

Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review. [PDF]

Front Immunol
Wan Z, Wang Y, Yang D.
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, Volume 183, Issue 6, Page 1271-1287, March 2026.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

JAK inhibitor tofacitinib alleviates secretory dysfunction and Th17/Treg imbalance in a Sjögren's disease murine model. [PDF]

Ann Med
Lin Y, Ou Y, Su J, Xu J, Liu C, He K, Zhou L, Wu D, Chen J.   +8 more
europepmc   +1 more source

S1‐Guideline for diagnosis and therapy of necrobiosis lipoidica

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 3, Page 429-436, March 2026.
Summary Necrobiosis lipoidica (NL) is a rare granulomatous skin disease of unknown etiology that occurs frequently in association with diabetes mellitus and other comorbidities. The predilection site is the lower leg, particularly the pretibial areas. The exact pathogenesis remains unclear.
Cornelia Erfurt‐Berge, Regina Renner, Melanie Peckruhn, Jörg Tittelbach, Dorothea Terhorst‐Molawi, Friederike Kauer, Joachim Dissemond   +6 more
wiley   +1 more source

A Comparative Study of Oral Tofacitinib and Oral Methotrexate in the Treatment of Patients With Moderate to Severe Chronic Plaque Psoriasis. [PDF]

Cureus
Unnikrishnan P, Vudayana K, Chintada D, Khatija Begum M, Chalamalasetty SS, Gullipalli P.   +5 more
europepmc   +1 more source